{"abstracts-retrieval-response": {"item": {"ait:process-info": {"ait:status": {"@state": "update", "@type": "core", "@stage": "S300"}, "ait:date-delivered": {"@day": "23", "@timestamp": "2021-02-23T17:24:20.000020-05:00", "@year": "2021", "@month": "02"}, "ait:date-sort": {"@day": "01", "@year": "2012", "@month": "12"}}, "bibrecord": {"head": {"author-group": [{"affiliation": {"city-group": "Bangkoknoi, Bangkok 10700", "country": "Thailand", "address-part": "2 Pranok Road", "@afid": "60011189", "@country": "tha", "organization": [{"$": "Division of Pediatric Nephrology"}, {"$": "Department of Pediatrics"}, {"$": "Faculty of Medicine Siriraj Hospital"}], "affiliation-id": {"@afid": "60011189", "@dptid": "103601809"}, "@dptid": "103601809"}, "author": [{"ce:given-name": "Suroj", "preferred-name": {"ce:given-name": "Suroj", "ce:initials": "S.", "ce:surname": "Supavekin", "ce:indexed-name": "Supavekin S."}, "@seq": "1", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Supavekin", "@auid": "12139961000", "ce:indexed-name": "Supavekin S."}, {"ce:given-name": "Worrarut", "preferred-name": {"ce:given-name": "Worrarut", "ce:initials": "W.", "ce:surname": "Tancharoen", "ce:indexed-name": "Tancharoen W."}, "@seq": "3", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Tancharoen", "@auid": "55567896600", "ce:indexed-name": "Tancharoen W."}, {"ce:given-name": "Anirut", "preferred-name": {"ce:given-name": "Anirut", "ce:initials": "A.", "ce:surname": "Pattaragarn", "ce:indexed-name": "Pattaragarn A."}, "@seq": "4", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Pattaragarn", "@auid": "7801330585", "ce:indexed-name": "Pattaragarn A."}, {"ce:given-name": "Achra", "preferred-name": {"ce:given-name": "Achra", "ce:initials": "A.", "ce:surname": "Sumboonnanonda", "ce:indexed-name": "Sumboonnanonda A."}, "@seq": "5", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Sumboonnanonda", "@auid": "6701903210", "ce:indexed-name": "Sumboonnanonda A."}]}, {"affiliation": {"city-group": "Bangkok", "country": "Thailand", "@afid": "60138776", "@country": "tha", "organization": [{"$": "Faculty of Finance"}, {"$": "Sasin Graduate Institute of Business Administration"}, {"$": "Chulalongkorn University"}], "affiliation-id": [{"@afid": "60138776", "@dptid": "125772769"}, {"@afid": "60028190"}], "@dptid": "125772769"}, "author": [{"ce:given-name": "Wantanee", "preferred-name": {"ce:given-name": "Wantanee", "ce:initials": "W.", "ce:surname": "Surapaitoolkorn", "ce:indexed-name": "Surapaitoolkorn W."}, "@seq": "2", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Surapaitoolkorn", "@auid": "55503262600", "ce:indexed-name": "Surapaitoolkorn W."}]}], "citation-title": "Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome", "abstracts": "Background: Reduced proteinuria results in delayed deterioration of renal function and remission of proteinuria predicts a good long-term prognosis in steroid-resistant nephrotic syndrome (SRNS). The aim of this study was to analyze the effects of the combined angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in reducing proteinuria in SRNS. Methods: A prospective study of eight patients with SRNS was conducted at the Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University from September 2003 to December 2007. Enalapril was given at 0.1 mg/kg/day and was increased by 0.1 mg/kg/day every 4 weeks up to 0.6 mg/kg/day (maximum 40 mg/day) and 1 mg/kg/day of losartan was added for 4 weeks and stepped up to 2 mg/kg/day (maximum 100 mg/day) for another 4 weeks. Results: There were five boys (62.5%) and three girls (37.5%). The mean age at diagnosis was 8.3 1 4.1 years (range 2.05-13 years) and age at enrollment was 11.7 1 3.8 years (range 6-16 years). Renal histology revealed seven focal segmental glomerulosclerosis and one immunoglobulin M nephropathy. The results showed significant reduction on mean spot urine protein: creatinine ratio from 9.6 1 2.3 to 3.6 1 1.6 (P < 0.05) and 24-h urine protein from 182.8 1 59.6 to 28.7 1 8.2 mg/m2/h (P < 0.05). Urine protein reduction ratio at the end of the study was 50% (P = 0.08). Serum cholesterol, albumin, potassium, blood pressure and renal function had no significant change. No clinical and laboratory side-effects were reported. Conclusion: Combined high-dose angiotensin II receptor blocker to high-dose angiotensin-converting enzyme inhibitor therapy is safe and effective in reducing proteinuria in childhood SRNS. However a large-scale study should be conducted to validate this result. \u00a9 2012 The Authors.", "correspondence": {"affiliation": {"city-group": "Bangkoknoi, Bangkok 10700", "country": "Thailand", "address-part": "2 Pranok Road", "@country": "tha", "organization": [{"$": "Division of Pediatric Nephrology"}, {"$": "Department of Pediatrics"}, {"$": "Faculty of Medicine Siriraj Hospital"}]}, "person": {"ce:initials": "S.", "ce:degrees": "Dr.", "ce:surname": "Supavekin", "ce:indexed-name": "Supavekin S."}}, "citation-info": {"author-keywords": {"author-keyword": [{"$": "Angiotensin II type I receptor blocker", "@xml:lang": "eng"}, {"$": "Angiotensin-converting enzyme inhibitor", "@xml:lang": "eng"}, {"$": "Steroid-resistant nephrotic syndrome", "@xml:lang": "eng"}]}, "citation-type": {"@code": "ar"}, "citation-language": {"@language": "English", "@xml:lang": "eng"}, "abstract-language": {"@language": "English", "@xml:lang": "eng"}}, "source": {"codencode": "JAMMF", "sourcetitle-abbrev": "Pediatr. Int.", "@country": "aus", "issn": [{"$": "13288067", "@type": "print"}, {"$": "1442200X", "@type": "electronic"}], "volisspag": {"voliss": {"@volume": "54", "@issue": "6"}, "pagerange": {"@first": "793", "@last": "797"}}, "@type": "j", "publicationyear": {"@first": "2012"}, "sourcetitle": "Pediatrics International", "@srcid": "15764", "publicationdate": {"month": "12", "year": "2012", "date-text": {"@xfab-added": "true", "$": "December 2012"}}}, "enhancement": {"classificationgroup": {"classifications": [{"@type": "EMCLASS", "classification": [{"classification-code": "28.3.1", "classification-description": "Urology and Nephrology; TREATMENT; Medical treatment"}, {"classification-code": "28.6", "classification-description": "Urology and Nephrology; KIDNEY AND KIDNEY FAILURE"}, {"classification-code": "37", "classification-description": "Drug Literature Index"}, {"classification-code": "7.12.8", "classification-description": "Pediatrics and Pediatric Surgery; ORGAN SYSTEMS; Urogenital system"}, {"classification-code": "7.3.1", "classification-description": "Pediatrics and Pediatric Surgery; TREATMENT; Medical treatment"}]}, {"@type": "ASJC", "classification": "2735"}, {"@type": "SUBJABBR", "classification": "MEDI"}]}, "chemicalgroup": {"chemicals": [{"@source": "esbd", "chemical": [{"cas-registry-number": "57-88-5", "chemical-name": "cholesterol"}, {"cas-registry-number": "75847-73-3", "chemical-name": "enalapril"}, {"cas-registry-number": "114798-26-4", "chemical-name": "losartan"}, {"cas-registry-number": "7440-09-7", "chemical-name": "potassium"}]}, {"@source": "nlm", "chemical": [{"cas-registry-number": "0", "chemical-name": "Angiotensin II Type 1 Receptor Blockers"}, {"cas-registry-number": "0", "chemical-name": "Angiotensin-Converting Enzyme Inhibitors"}]}]}}}, "item-info": {"copyright": [{"$": "Copyright 2014 Elsevier B.V., All rights reserved.", "@type": "Elsevier"}, {"$": "MEDLINE\u00ae is the source for the MeSH terms of this document.", "@type": "Medline Descriptors"}], "dbcollection": [{"$": "EMBASE"}, {"$": "NURSNG"}, {"$": "MEDL"}, {"$": "SCOPUS"}, {"$": "Scopusbase"}], "history": {"date-created": {"@day": "29", "@year": "2013", "@month": "01"}}, "itemidlist": {"itemid": [{"$": "368172013", "@idtype": "PUI"}, {"$": "2013058514", "@idtype": "EMBASE"}, {"$": "2013025511", "@idtype": "NURSNG"}, {"$": "22621380", "@idtype": "MEDL"}, {"$": "84872793609", "@idtype": "SCP"}, {"$": "84872793609", "@idtype": "SGR"}], "ce:doi": "10.1111/j.1442-200X.2012.03668.x"}}, "tail": {"bibliography": {"@refcount": "40", "reference": [{"ref-fulltext": "Mendoza SA, Reznik VM, Grisworld WR, Krensky AM, Yorgin PD, Tune BM. Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents. Pediatr. Nephrol. 1990; 4: 303-7.", "@id": "1", "ref-info": {"ref-publicationyear": {"@first": "1990"}, "ref-title": {"ref-titletext": "Treatment of steroid-resistant focal segmental glomerulosclerosis with pulse methylprednisolone and alkylating agents"}, "refd-itemidlist": {"itemid": {"$": "0025183259", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "4"}, "pagerange": {"@first": "303", "@last": "307"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.A.", "@_fa": "true", "ce:surname": "Mendoza", "ce:indexed-name": "Mendoza S.A."}, {"@seq": "2", "ce:initials": "V.M.", "@_fa": "true", "ce:surname": "Reznik", "ce:indexed-name": "Reznik V.M."}, {"@seq": "3", "ce:initials": "W.R.", "@_fa": "true", "ce:surname": "Grisworld", "ce:indexed-name": "Grisworld W.R."}, {"@seq": "4", "ce:initials": "A.M.", "@_fa": "true", "ce:surname": "Krensky", "ce:indexed-name": "Krensky A.M."}, {"@seq": "5", "ce:initials": "P.D.", "@_fa": "true", "ce:surname": "Yorgin", "ce:indexed-name": "Yorgin P.D."}, {"@seq": "6", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Tune", "ce:indexed-name": "Tune B.M."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am. J. Kidney Dis. 1998; 32: 72-9.", "@id": "2", "ref-info": {"ref-publicationyear": {"@first": "1998"}, "ref-title": {"ref-titletext": "Long-term outcome in children and adults with classic focal segmental glomerulosclerosis"}, "refd-itemidlist": {"itemid": {"$": "0031837403", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32"}, "pagerange": {"@first": "72", "@last": "79"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.C.", "@_fa": "true", "ce:surname": "Cattran", "ce:indexed-name": "Cattran D.C."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Rao", "ce:indexed-name": "Rao P."}]}, "ref-sourcetitle": "Am. J. Kidney Dis."}}, {"ref-fulltext": "Praga M, Morales E. Renal damage associated with proteinuria. Kidney Int. 2002; 62 (Suppl. 82): S42-6.", "@id": "3", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Renal damage associated with proteinuria"}, "refd-itemidlist": {"itemid": {"$": "0036435819", "@idtype": "SGR"}}, "ref-volisspag": {"pages": "S42-6", "voliss": {"@volume": "62", "@issue": "SUPPL. 82"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Praga", "ce:indexed-name": "Praga M."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Morales", "ce:indexed-name": "Morales E."}]}, "ref-sourcetitle": "Kidney Int."}}, {"ref-fulltext": "Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuria chronic nephropathies. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Kidney Int. 1998; 53: 1209-16.", "@id": "4", "ref-info": {"ref-publicationyear": {"@first": "1998"}, "ref-title": {"ref-titletext": "Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuria chronic nephropathiesGruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN)"}, "refd-itemidlist": {"itemid": {"$": "0031819895", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "53"}, "pagerange": {"@first": "1209", "@last": "1216"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ruggenenti", "ce:indexed-name": "Ruggenenti P."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Perna", "ce:indexed-name": "Perna A."}, {"@seq": "3", "ce:initials": "L.", "@_fa": "true", "ce:surname": "Mosconi", "ce:indexed-name": "Mosconi L."}, {"@seq": "4", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Pisoni", "ce:indexed-name": "Pisoni R."}, {"@seq": "5", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Remuzzi", "ce:indexed-name": "Remuzzi G."}]}, "ref-sourcetitle": "Kidney Int."}}, {"ref-fulltext": "Martinelli R, Okumura AS, Pereira LJ, Rocha H. Primary focal segmental glomerulosclerosis in children. Prognostic factors. Pediatr. Nephrol. 2001; 16: 658-61.", "@id": "5", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Primary focal segmental glomerulosclerosis in children. Prognostic factors"}, "refd-itemidlist": {"itemid": {"$": "0034897287", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "16"}, "pagerange": {"@first": "658", "@last": "661"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Martinelli", "ce:indexed-name": "Martinelli R."}, {"@seq": "2", "ce:initials": "A.S.", "@_fa": "true", "ce:surname": "Okumura", "ce:indexed-name": "Okumura A.S."}, {"@seq": "3", "ce:initials": "L.J.", "@_fa": "true", "ce:surname": "Pereira", "ce:indexed-name": "Pereira L.J."}, {"@seq": "4", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Rocha", "ce:indexed-name": "Rocha H."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Sica DA, Ripley E. Angiotensin-converting enzyme inhibitors. In: Izzo JL, Black HR (eds). Hypertension Primer, 2nd edn. Lippincot Williams & Wilkins, Baltimore, MD, 1999; 372-6.", "@id": "6", "ref-info": {"ref-publicationyear": {"@first": "1999"}, "ref-title": {"ref-titletext": "Angiotensin-converting enzyme inhibitors"}, "refd-itemidlist": {"itemid": {"$": "1542357886", "@idtype": "SGR"}}, "ref-volisspag": {"pagerange": {"@first": "372", "@last": "376"}}, "ref-text": "Izzo JL, Black HR (eds) 2nd edn. Lippincot Williams & Wilkins, Baltimore, MD", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.A.", "@_fa": "true", "ce:surname": "Sica", "ce:indexed-name": "Sica D.A."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Ripley", "ce:indexed-name": "Ripley E."}]}, "ref-sourcetitle": "Hypertension Primer"}}, {"ref-fulltext": "Lama G, Esposito Salsano M, Pedulla M, Grassia C, Ruocco G. Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up. Pediatr. Nephrol. 1997; 11: 714-18.", "@id": "7", "ref-info": {"ref-publicationyear": {"@first": "1997"}, "ref-title": {"ref-titletext": "Angiotensin converting enzyme inhibitors and reflux nephropathy: 2-year follow-up"}, "refd-itemidlist": {"itemid": {"$": "0030722095", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "11"}, "pagerange": {"@first": "714", "@last": "718"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Lama", "ce:indexed-name": "Lama G."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Esposito Salsano", "ce:indexed-name": "Esposito Salsano M."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Pedulla", "ce:indexed-name": "Pedulla M."}, {"@seq": "4", "ce:initials": "C.", "@_fa": "true", "ce:surname": "Grassia", "ce:indexed-name": "Grassia C."}, {"@seq": "5", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Ruocco", "ce:indexed-name": "Ruocco G."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. Ann. Intern. Med. 2001; 135: 73-7.", "@id": "8", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease"}, "refd-itemidlist": {"itemid": {"$": "0035902622", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "135"}, "pagerange": {"@first": "73", "@last": "77"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.H.", "@_fa": "true", "ce:surname": "Jafar", "ce:indexed-name": "Jafar T.H."}, {"@seq": "2", "ce:initials": "C.H.", "@_fa": "true", "ce:surname": "Schmid", "ce:indexed-name": "Schmid C.H."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Landa", "ce:indexed-name": "Landa M."}], "et-al": null}, "ref-sourcetitle": "Ann. Intern. Med."}}, {"ref-fulltext": "Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, Morales E, Hern\u00e1ndez E. Treatment of Ig A nephropathy with ACE inhibitors: a randomized and controlled trial. J. Am. Soc. Nephrol. 2003; 14: 1578-83.", "@id": "9", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Treatment of ig A nephropathy with ACE inhibitors: A randomized and controlled trial"}, "refd-itemidlist": {"itemid": {"$": "0038512403", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14"}, "pagerange": {"@first": "1578", "@last": "1583"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Praga", "ce:indexed-name": "Praga M."}, {"@seq": "2", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Guti\u00e9rrez", "ce:indexed-name": "Gutierrez E."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Gonz\u00e1lez", "ce:indexed-name": "Gonzalez E."}, {"@seq": "4", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Morales", "ce:indexed-name": "Morales E."}, {"@seq": "5", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Hern\u00e1ndez", "ce:indexed-name": "Hernandez E."}]}, "ref-sourcetitle": "J. Am. Soc. Nephrol."}}, {"ref-fulltext": "Proesmans W, Van Dyck M. Enalapril in children with Alport syndrome. Pediatr. Nephrol. 2004; 19: 271-5.", "@id": "10", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Enalapril in children with alport syndrome"}, "refd-itemidlist": {"itemid": {"$": "1542330045", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19"}, "pagerange": {"@first": "271", "@last": "275"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Proesmans", "ce:indexed-name": "Proesmans W."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Van Dyck", "ce:indexed-name": "Van Dyck M."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Trachtman H, Gauthier B. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease. J. Pediatr. 1988; 112: 295-8.", "@id": "11", "ref-info": {"ref-publicationyear": {"@first": "1988"}, "ref-title": {"ref-titletext": "Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease"}, "refd-itemidlist": {"itemid": {"$": "0023902719", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "112"}, "pagerange": {"@first": "295", "@last": "298"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Trachtman", "ce:indexed-name": "Trachtman H."}, {"@seq": "2", "ce:initials": "B.", "@_fa": "true", "ce:surname": "Gauthier", "ce:indexed-name": "Gauthier B."}]}, "ref-sourcetitle": "J. Pediatr."}}, {"ref-fulltext": "Milliner DS, Morgenstern BZ. Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 1991; 5: 587-90.", "@id": "12", "ref-info": {"ref-publicationyear": {"@first": "1991"}, "ref-title": {"ref-titletext": "Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome"}, "refd-itemidlist": {"itemid": {"$": "0025837527", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "5"}, "pagerange": {"@first": "587", "@last": "590"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.S.", "@_fa": "true", "ce:surname": "Milliner", "ce:indexed-name": "Milliner D.S."}, {"@seq": "2", "ce:initials": "B.Z.", "@_fa": "true", "ce:surname": "Morgenstern", "ce:indexed-name": "Morgenstern B.Z."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Proesmans W, Van Wambeke I, Van Dyck M. Long-term therapy with enalapril in patients with nephrotic-range proteinuria. Pediatr. Nephrol. 1996; 10: 587-9.", "@id": "13", "ref-info": {"ref-publicationyear": {"@first": "1996"}, "ref-title": {"ref-titletext": "Long-term therapy with enalapril in patients with nephrotic-range proteinuria"}, "refd-itemidlist": {"itemid": {"$": "0029783422", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "10"}, "pagerange": {"@first": "587", "@last": "589"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Proesmans", "ce:indexed-name": "Proesmans W."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Van Wambeke", "ce:indexed-name": "Van Wambeke I."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Van Dyck", "ce:indexed-name": "Van Dyck M."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Lama G, Luongo I, Piscitelli A, Esposito Salsano M. Enalapril: antiproteinuric effect in children with nephrotic syndrome. Clin. Nephrol. 2000; 53: 432-6.", "@id": "14", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Enalapril: Antiproteinuric effect in children with nephrotic syndrome"}, "refd-itemidlist": {"itemid": {"$": "0034129981", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "53"}, "pagerange": {"@first": "432", "@last": "436"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Lama", "ce:indexed-name": "Lama G."}, {"@seq": "2", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Luongo", "ce:indexed-name": "Luongo I."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Piscitelli", "ce:indexed-name": "Piscitelli A."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Esposito Salsano", "ce:indexed-name": "Esposito Salsano M."}]}, "ref-sourcetitle": "Clin. Nephrol."}}, {"ref-fulltext": "Delucchi A, Cano F, Rodriquez E, Wolff E, Gonzalez X, Cumsille MA. Enalapril and prednisone in children with nephrotic-range proteinuria. Pediatr. Nephrol. 2000; 14: 1088-91.", "@id": "15", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Enalapril and prednisone in children with nephrotic-range proteinuria"}, "refd-itemidlist": {"itemid": {"$": "0033818834", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "14"}, "pagerange": {"@first": "1088", "@last": "1091"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Delucchi", "ce:indexed-name": "Delucchi A."}, {"@seq": "2", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Cano", "ce:indexed-name": "Cano F."}, {"@seq": "3", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Rodriquez", "ce:indexed-name": "Rodriquez E."}, {"@seq": "4", "ce:initials": "E.", "@_fa": "true", "ce:surname": "Wolff", "ce:indexed-name": "Wolff E."}, {"@seq": "5", "ce:initials": "X.", "@_fa": "true", "ce:surname": "Gonzalez", "ce:indexed-name": "Gonzalez X."}, {"@seq": "6", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Cumsille", "ce:indexed-name": "Cumsille M.A."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Bagga A, Mudigoudar BD, Hari P, Vasudev V. Enalapril dosage in steroid-resistant nephrotic syndrome. Pediatr. Nephrol. 2004; 19: 45-50.", "@id": "16", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Enalapril dosage in steroid-resistant nephrotic syndrome"}, "refd-itemidlist": {"itemid": {"$": "0347899276", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19"}, "pagerange": {"@first": "45", "@last": "50"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Bagga", "ce:indexed-name": "Bagga A."}, {"@seq": "2", "ce:initials": "B.D.", "@_fa": "true", "ce:surname": "Mudigoudar", "ce:indexed-name": "Mudigoudar B.D."}, {"@seq": "3", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Hari", "ce:indexed-name": "Hari P."}, {"@seq": "4", "ce:initials": "V.", "@_fa": "true", "ce:surname": "Vasudev", "ce:indexed-name": "Vasudev V."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Ferrario CM. Angiotensin formation and degradation. In: Izzo JL, Black HR (eds). Hypertension Primer, 2nd edn. Lippincot Williams & Wilkins, Baltimore, MD, 1999; 21-2.", "@id": "17", "ref-info": {"ref-publicationyear": {"@first": "1999"}, "ref-title": {"ref-titletext": "Angiotensin formation and degradation"}, "refd-itemidlist": {"itemid": {"$": "0010135449", "@idtype": "SGR"}}, "ref-volisspag": {"pagerange": {"@first": "21", "@last": "22"}}, "ref-text": "Izzo JL, Black HR (eds) 2nd edn. Lippincot Williams & Wilkins, Baltimore, MD", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.M.", "@_fa": "true", "ce:surname": "Ferrario", "ce:indexed-name": "Ferrario C.M."}]}, "ref-sourcetitle": "Hypertension Primer"}}, {"ref-fulltext": "Hilgers KF, Mann JFE. ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease. J. Am. Soc. Nephrol. 2002; 13: 1100-8.", "@id": "18", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "ACE inhibitors versus AT1 receptor antagonists in patients with chronic renal disease"}, "refd-itemidlist": {"itemid": {"$": "0036209899", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "13"}, "pagerange": {"@first": "1100", "@last": "1108"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.F.", "@_fa": "true", "ce:surname": "Hilgers", "ce:indexed-name": "Hilgers K.F."}, {"@seq": "2", "ce:initials": "J.F.E.", "@_fa": "true", "ce:surname": "Mann", "ce:indexed-name": "Mann J.F.E."}]}, "ref-sourcetitle": "J. Am. Soc. Nephrol."}}, {"ref-fulltext": "Weber MA. Angiotensin II receptor blockers. In: Izzo JL, Black HR (eds). Hypertension Primer, 2nd edn. Lippincot Williams & Wilkins, Baltimore, MD, 1999; 377-8.", "@id": "19", "ref-info": {"ref-publicationyear": {"@first": "1999"}, "ref-title": {"ref-titletext": "Angiotensin II receptor blockers"}, "refd-itemidlist": {"itemid": {"$": "0001302374", "@idtype": "SGR"}}, "ref-volisspag": {"pagerange": {"@first": "377", "@last": "378"}}, "ref-text": "Izzo JL, Black HR (eds) 2nd edn. Lippincot Williams & Wilkins, Baltimore, MD", "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.A.", "@_fa": "true", "ce:surname": "Weber", "ce:indexed-name": "Weber M.A."}]}, "ref-sourcetitle": "Hypertension Primer"}}, {"ref-fulltext": "Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001; 345: 861-9.", "@id": "20", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy"}, "refd-itemidlist": {"itemid": {"$": "0035922441", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "345"}, "pagerange": {"@first": "861", "@last": "869"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "B.M.", "@_fa": "true", "ce:surname": "Brenner", "ce:indexed-name": "Brenner B.M."}, {"@seq": "2", "ce:initials": "M.E.", "@_fa": "true", "ce:surname": "Cooper", "ce:indexed-name": "Cooper M.E."}, {"@seq": "3", "ce:initials": "D.", "@_fa": "true", "ce:surname": "De Zeeuw", "ce:indexed-name": "De Zeeuw D."}], "et-al": null}, "ref-sourcetitle": "N. Engl. J. Med."}}, {"ref-fulltext": "Remuzzi G, Ruggenenti P, Perna A et al. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J. Am. Soc. Nephrol. 2004; 15: 3117-25.", "@id": "21", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results"}, "refd-itemidlist": {"itemid": {"$": "9644294206", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15"}, "pagerange": {"@first": "3117", "@last": "3125"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Remuzzi", "ce:indexed-name": "Remuzzi G."}, {"@seq": "2", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ruggenenti", "ce:indexed-name": "Ruggenenti P."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Perna", "ce:indexed-name": "Perna A."}], "et-al": null}, "ref-sourcetitle": "J. Am. Soc. Nephrol."}}, {"ref-fulltext": "Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.", "@id": "22", "ref-info": {"ref-publicationyear": {"@first": "2000"}, "ref-title": {"ref-titletext": "Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study"}, "refd-itemidlist": {"itemid": {"$": "0034627208", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "321"}, "pagerange": {"@first": "1440", "@last": "1444"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.E.", "@_fa": "true", "ce:surname": "Mogensen", "ce:indexed-name": "Mogensen C.E."}, {"@seq": "2", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Neldam", "ce:indexed-name": "Neldam S."}, {"@seq": "3", "ce:initials": "I.", "@_fa": "true", "ce:surname": "Tikkanen", "ce:indexed-name": "Tikkanen I."}], "et-al": null}, "ref-sourcetitle": "BMJ"}}, {"ref-fulltext": "Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D. Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int. 2002; 62: 1020-5.", "@id": "23", "ref-info": {"ref-publicationyear": {"@first": "2002"}, "ref-title": {"ref-titletext": "Dual renin-angiotensin system blockade at optimal doses for proteinuria"}, "refd-itemidlist": {"itemid": {"$": "0036419739", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "62"}, "pagerange": {"@first": "1020", "@last": "1025"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.D.", "@_fa": "true", "ce:surname": "Laverman", "ce:indexed-name": "Laverman G.D."}, {"@seq": "2", "ce:initials": "G.", "@_fa": "true", "ce:surname": "Navis", "ce:indexed-name": "Navis G."}, {"@seq": "3", "ce:initials": "R.H.", "@_fa": "true", "ce:surname": "Henning", "ce:indexed-name": "Henning R.H."}, {"@seq": "4", "ce:initials": "P.E.", "@_fa": "true", "ce:surname": "De Jong", "ce:indexed-name": "De Jong P.E."}, {"@seq": "5", "ce:initials": "D.", "@_fa": "true", "ce:surname": "De Zeeuw", "ce:indexed-name": "De Zeeuw D."}]}, "ref-sourcetitle": "Kidney Int."}}, {"ref-fulltext": "Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATIVE): a randomized controlled trial. Lancet 2003; 361: 117-24.", "@id": "24", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATIVE): A randomized controlled trial"}, "refd-itemidlist": {"itemid": {"$": "0037431774", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "361"}, "pagerange": {"@first": "117", "@last": "124"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Nakao", "ce:indexed-name": "Nakao N."}, {"@seq": "2", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Yoshimura", "ce:indexed-name": "Yoshimura A."}, {"@seq": "3", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Morita", "ce:indexed-name": "Morita H."}, {"@seq": "4", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Takada", "ce:indexed-name": "Takada M."}, {"@seq": "5", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Kayano", "ce:indexed-name": "Kayano T."}, {"@seq": "6", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Ideura", "ce:indexed-name": "Ideura T."}]}, "ref-sourcetitle": "Lancet"}}, {"ref-fulltext": "Ferrari P. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology 2007; 12: 81-9.", "@id": "25", "ref-info": {"ref-publicationyear": {"@first": "2007"}, "ref-title": {"ref-titletext": "Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease"}, "refd-itemidlist": {"itemid": {"$": "33846973650", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "12"}, "pagerange": {"@first": "81", "@last": "89"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ferrari", "ce:indexed-name": "Ferrari P."}]}, "ref-sourcetitle": "Nephrology"}}, {"ref-fulltext": "Litwin M, Grenda R, \u015aladowska J, Antoniewicz J. Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors. Pediatr. Nephrol. 2006; 21: 1716-22.", "@id": "26", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors"}, "refd-itemidlist": {"itemid": {"$": "33748695980", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21"}, "pagerange": {"@first": "1716", "@last": "1722"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Litwin", "ce:indexed-name": "Litwin M."}, {"@seq": "2", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Grenda", "ce:indexed-name": "Grenda R."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "\u015aladowska", "ce:indexed-name": "Sladowska J."}, {"@seq": "4", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Antoniewicz", "ce:indexed-name": "Antoniewicz J."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Seeman T, Pohl M, Misselwitz J, John U. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors. Kidney Blood Press. Res. 2009; 32: 440-4.", "@id": "27", "ref-info": {"ref-publicationyear": {"@first": "2009"}, "ref-title": {"ref-titletext": "Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with angiotensin-converting enzyme inhibitors"}, "refd-itemidlist": {"itemid": {"$": "72049088306", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "32"}, "pagerange": {"@first": "440", "@last": "444"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Seeman", "ce:indexed-name": "Seeman T."}, {"@seq": "2", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Pohl", "ce:indexed-name": "Pohl M."}, {"@seq": "3", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Misselwitz", "ce:indexed-name": "Misselwitz J."}, {"@seq": "4", "ce:initials": "U.", "@_fa": "true", "ce:surname": "John", "ce:indexed-name": "John U."}]}, "ref-sourcetitle": "Kidney Blood Press. Res."}}, {"ref-fulltext": "Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr. Clin. North Am. 1987; 34: 571-90.", "@id": "28", "ref-info": {"ref-publicationyear": {"@first": "1987"}, "ref-title": {"ref-titletext": "The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents"}, "refd-itemidlist": {"itemid": {"$": "0023179130", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "34"}, "pagerange": {"@first": "571", "@last": "590"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "G.J.", "@_fa": "true", "ce:surname": "Schwartz", "ce:indexed-name": "Schwartz G.J."}, {"@seq": "2", "ce:initials": "L.P.", "@_fa": "true", "ce:surname": "Brion", "ce:indexed-name": "Brion L.P."}, {"@seq": "3", "ce:initials": "A.", "@_fa": "true", "ce:surname": "Spitzer", "ce:indexed-name": "Spitzer A."}]}, "ref-sourcetitle": "Pediatr. Clin. North Am."}}, {"ref-fulltext": "National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a Working Group Report from the National High Blood Pressure Education Program. Pediatrics 1996; 98: 649-58.", "@id": "29", "ref-info": {"ref-publicationyear": {"@first": "1996"}, "refd-itemidlist": {"itemid": {"$": "0029800129", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "98"}, "pagerange": {"@first": "649", "@last": "658"}}, "ref-text": "National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a Working Group Report from the National High Blood Pressure Education Program", "ref-sourcetitle": "Pediatrics"}}, {"ref-fulltext": "Hilgers KF, Dotsch J, Rascher W, Mann JFE. Treatment strategies in patients with chronic renal disease: aCE inhibitors, angiotensin receptor antagonists, or both? Pediatr. Nephrol. 2004; 19: 956-61.", "@id": "30", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Treatment strategies in patients with chronic renal disease: Ace inhibitors, angiotensin receptor antagonists, or both?"}, "refd-itemidlist": {"itemid": {"$": "4544232442", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "19"}, "pagerange": {"@first": "956", "@last": "961"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.F.", "@_fa": "true", "ce:surname": "Hilgers", "ce:indexed-name": "Hilgers K.F."}, {"@seq": "2", "ce:initials": "J.", "@_fa": "true", "ce:surname": "Dotsch", "ce:indexed-name": "Dotsch J."}, {"@seq": "3", "ce:initials": "W.", "@_fa": "true", "ce:surname": "Rascher", "ce:indexed-name": "Rascher W."}, {"@seq": "4", "ce:initials": "J.F.E.", "@_fa": "true", "ce:surname": "Mann", "ce:indexed-name": "Mann J.F.E."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "White CT, Macpherson CF, Hurley RM, Matsell DG. Antiproteinuric effects of enalapril and losartan: a pilot study. Pediatr. Nephrol. 2003; 18: 1038-43.", "@id": "31", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Antiproteinuric effects of enalapril and losartan: A pilot study"}, "refd-itemidlist": {"itemid": {"$": "0141954962", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "18"}, "pagerange": {"@first": "1038", "@last": "1043"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "C.T.", "@_fa": "true", "ce:surname": "White", "ce:indexed-name": "White C.T."}, {"@seq": "2", "ce:initials": "C.F.", "@_fa": "true", "ce:surname": "Macpherson", "ce:indexed-name": "Macpherson C.F."}, {"@seq": "3", "ce:initials": "R.M.", "@_fa": "true", "ce:surname": "Hurley", "ce:indexed-name": "Hurley R.M."}, {"@seq": "4", "ce:initials": "D.G.", "@_fa": "true", "ce:surname": "Matsell", "ce:indexed-name": "Matsell D.G."}]}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Gipson DS, Chin H, Presler TP et al. Differential risk of remission and ESRD in childhood FSGS. Pediatr. Nephrol. 2006; 21: 344-9.", "@id": "32", "ref-info": {"ref-publicationyear": {"@first": "2006"}, "ref-title": {"ref-titletext": "Differential risk of remission and ESRD in childhood FSGS"}, "refd-itemidlist": {"itemid": {"$": "33244498085", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "21"}, "pagerange": {"@first": "344", "@last": "349"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "D.S.", "@_fa": "true", "ce:surname": "Gipson", "ce:indexed-name": "Gipson D.S."}, {"@seq": "2", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Chin", "ce:indexed-name": "Chin H."}, {"@seq": "3", "ce:initials": "T.P.", "@_fa": "true", "ce:surname": "Presler", "ce:indexed-name": "Presler T.P."}], "et-al": null}, "ref-sourcetitle": "Pediatr. Nephrol."}}, {"ref-fulltext": "Tanaka H, Suzuki K, Nakahata T et al. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy. Pediatr. Int. 2004; 46: 576-9.", "@id": "33", "ref-info": {"ref-publicationyear": {"@first": "2004"}, "ref-title": {"ref-titletext": "Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy"}, "refd-itemidlist": {"itemid": {"$": "7044264909", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "46"}, "pagerange": {"@first": "576", "@last": "579"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "H.", "@_fa": "true", "ce:surname": "Tanaka", "ce:indexed-name": "Tanaka H."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Suzuki", "ce:indexed-name": "Suzuki K."}, {"@seq": "3", "ce:initials": "T.", "@_fa": "true", "ce:surname": "Nakahata", "ce:indexed-name": "Nakahata T."}], "et-al": null}, "ref-sourcetitle": "Pediatr. Int."}}, {"ref-fulltext": "Yang Y, Ohta K, Shimizu M et al. Treatment with low-dose angiotensin-converting-enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin. Nephrol. 2005; 64: 35-40.", "@id": "34", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Treatment with low-dose angiotensin-converting-enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy"}, "refd-itemidlist": {"itemid": {"$": "22144493381", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "64"}, "pagerange": {"@first": "35", "@last": "40"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "Y.", "@_fa": "true", "ce:surname": "Yang", "ce:indexed-name": "Yang Y."}, {"@seq": "2", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Ohta", "ce:indexed-name": "Ohta K."}, {"@seq": "3", "ce:initials": "M.", "@_fa": "true", "ce:surname": "Shimizu", "ce:indexed-name": "Shimizu M."}], "et-al": null}, "ref-sourcetitle": "Clin. Nephrol."}}, {"ref-fulltext": "Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int. 2005; 68: 1190-8.", "@id": "35", "ref-info": {"ref-publicationyear": {"@first": "2005"}, "ref-title": {"ref-titletext": "Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria"}, "refd-itemidlist": {"itemid": {"$": "30944466929", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "68"}, "pagerange": {"@first": "1190", "@last": "1198"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Rossing", "ce:indexed-name": "Rossing K."}, {"@seq": "2", "ce:initials": "K.J.", "@_fa": "true", "ce:surname": "Schjoedt", "ce:indexed-name": "Schjoedt K.J."}, {"@seq": "3", "ce:initials": "B.R.", "@_fa": "true", "ce:surname": "Jensen", "ce:indexed-name": "Jensen B.R."}, {"@seq": "4", "ce:initials": "F.", "@_fa": "true", "ce:surname": "Boomsma", "ce:indexed-name": "Boomsma F."}, {"@seq": "5", "ce:initials": "H.H.", "@_fa": "true", "ce:surname": "Parving", "ce:indexed-name": "Parving H.H."}]}, "ref-sourcetitle": "Kidney Int."}}, {"ref-fulltext": "Hou FF, Zhou QG. Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection. Nephrology 2010; 15: 57-60.", "@id": "36", "ref-info": {"ref-publicationyear": {"@first": "2010"}, "ref-title": {"ref-titletext": "Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection"}, "refd-itemidlist": {"itemid": {"$": "77952639446", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "15"}, "pagerange": {"@first": "57", "@last": "60"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "F.F.", "@_fa": "true", "ce:surname": "Hou", "ce:indexed-name": "Hou F.F."}, {"@seq": "2", "ce:initials": "Q.G.", "@_fa": "true", "ce:surname": "Zhou", "ce:indexed-name": "Zhou Q.G."}]}, "ref-sourcetitle": "Nephrology"}}, {"ref-fulltext": "Ginsberg JM, Chang BS, Matarese RA, Garella S. Use of single voided urine samples to estimate quantitative proteinuria. N. Engl. J. Med. 1983; 309: 1543-6.", "@id": "37", "ref-info": {"ref-publicationyear": {"@first": "1983"}, "ref-title": {"ref-titletext": "Use of single voided urine samples to estimate quantitative proteinuria"}, "refd-itemidlist": {"itemid": {"$": "0021070402", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "309"}, "pagerange": {"@first": "1543", "@last": "1546"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "J.M.", "@_fa": "true", "ce:surname": "Ginsberg", "ce:indexed-name": "Ginsberg J.M."}, {"@seq": "2", "ce:initials": "B.S.", "@_fa": "true", "ce:surname": "Chang", "ce:indexed-name": "Chang B.S."}, {"@seq": "3", "ce:initials": "R.A.", "@_fa": "true", "ce:surname": "Matarese", "ce:indexed-name": "Matarese R.A."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Garella", "ce:indexed-name": "Garella S."}]}, "ref-sourcetitle": "N. Engl. J. Med."}}, {"ref-fulltext": "Schwab SJ, Christensen LR, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch. Intern. Med. 1987; 147: 943-4.", "@id": "38", "ref-info": {"ref-publicationyear": {"@first": "1987"}, "ref-title": {"ref-titletext": "Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples"}, "refd-itemidlist": {"itemid": {"$": "0023221090", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "147"}, "pagerange": {"@first": "943", "@last": "944"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "S.J.", "@_fa": "true", "ce:surname": "Schwab", "ce:indexed-name": "Schwab S.J."}, {"@seq": "2", "ce:initials": "L.R.", "@_fa": "true", "ce:surname": "Christensen", "ce:indexed-name": "Christensen L.R."}, {"@seq": "3", "ce:initials": "K.", "@_fa": "true", "ce:surname": "Dougherty", "ce:indexed-name": "Dougherty K."}, {"@seq": "4", "ce:initials": "S.", "@_fa": "true", "ce:surname": "Klahr", "ce:indexed-name": "Klahr S."}]}, "ref-sourcetitle": "Arch. Intern. Med."}}, {"ref-fulltext": "Agarwal R. Add-on angiotensin receptor blockade with maximized ACE inhibition. Kidney Int. 2001; 59: 2282-9.", "@id": "39", "ref-info": {"ref-publicationyear": {"@first": "2001"}, "ref-title": {"ref-titletext": "Add-on angiotensin receptor blockade with maximized ACE inhibition"}, "refd-itemidlist": {"itemid": {"$": "0035008799", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "59"}, "pagerange": {"@first": "2282", "@last": "2289"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Agarwal", "ce:indexed-name": "Agarwal R."}]}, "ref-sourcetitle": "Kidney Int."}}, {"ref-fulltext": "Ruggenenti P, Mise N, Pisoni R et al. Diverse effects of increasing lisinopril dose on lipid abnormalities in chronic nephropathies. Circulation 2003; 107: 586-92.", "@id": "40", "ref-info": {"ref-publicationyear": {"@first": "2003"}, "ref-title": {"ref-titletext": "Diverse effects of increasing lisinopril dose on lipid abnormalities in chronic nephropathies"}, "refd-itemidlist": {"itemid": {"$": "0037417936", "@idtype": "SGR"}}, "ref-volisspag": {"voliss": {"@volume": "107"}, "pagerange": {"@first": "586", "@last": "592"}}, "ref-authors": {"author": [{"@seq": "1", "ce:initials": "P.", "@_fa": "true", "ce:surname": "Ruggenenti", "ce:indexed-name": "Ruggenenti P."}, {"@seq": "2", "ce:initials": "N.", "@_fa": "true", "ce:surname": "Mise", "ce:indexed-name": "Mise N."}, {"@seq": "3", "ce:initials": "R.", "@_fa": "true", "ce:surname": "Pisoni", "ce:indexed-name": "Pisoni R."}], "et-al": null}, "ref-sourcetitle": "Circulation"}}]}}}}, "affiliation": [{"affiliation-city": "Bangkok", "@id": "60138776", "affilname": "Sasin School of Management, Bangkok", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138776", "affiliation-country": "Thailand"}, {"affiliation-city": "Bangkok", "@id": "60011189", "affilname": "Faculty of Medicine Siriraj Hospital, Mahidol University", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189", "affiliation-country": "Thailand"}], "coredata": {"srctype": "j", "eid": "2-s2.0-84872793609", "dc:description": "Background: Reduced proteinuria results in delayed deterioration of renal function and remission of proteinuria predicts a good long-term prognosis in steroid-resistant nephrotic syndrome (SRNS). The aim of this study was to analyze the effects of the combined angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker in reducing proteinuria in SRNS. Methods: A prospective study of eight patients with SRNS was conducted at the Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University from September 2003 to December 2007. Enalapril was given at 0.1 mg/kg/day and was increased by 0.1 mg/kg/day every 4 weeks up to 0.6 mg/kg/day (maximum 40 mg/day) and 1 mg/kg/day of losartan was added for 4 weeks and stepped up to 2 mg/kg/day (maximum 100 mg/day) for another 4 weeks. Results: There were five boys (62.5%) and three girls (37.5%). The mean age at diagnosis was 8.3 1 4.1 years (range 2.05-13 years) and age at enrollment was 11.7 1 3.8 years (range 6-16 years). Renal histology revealed seven focal segmental glomerulosclerosis and one immunoglobulin M nephropathy. The results showed significant reduction on mean spot urine protein: creatinine ratio from 9.6 1 2.3 to 3.6 1 1.6 (P < 0.05) and 24-h urine protein from 182.8 1 59.6 to 28.7 1 8.2 mg/m2/h (P < 0.05). Urine protein reduction ratio at the end of the study was 50% (P = 0.08). Serum cholesterol, albumin, potassium, blood pressure and renal function had no significant change. No clinical and laboratory side-effects were reported. Conclusion: Combined high-dose angiotensin II receptor blocker to high-dose angiotensin-converting enzyme inhibitor therapy is safe and effective in reducing proteinuria in childhood SRNS. However a large-scale study should be conducted to validate this result. \u00a9 2012 The Authors.", "pubmed-id": "22621380", "prism:coverDate": "2012-12-01", "prism:aggregationType": "Journal", "prism:url": "https://api.elsevier.com/content/abstract/scopus_id/84872793609", "dc:creator": {"author": [{"ce:given-name": "Suroj", "preferred-name": {"ce:given-name": "Suroj", "ce:initials": "S.", "ce:surname": "Supavekin", "ce:indexed-name": "Supavekin S."}, "@seq": "1", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60011189", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189"}, "ce:surname": "Supavekin", "@auid": "12139961000", "author-url": "https://api.elsevier.com/content/author/author_id/12139961000", "ce:indexed-name": "Supavekin S."}]}, "link": [{"@_fa": "true", "@rel": "self", "@href": "https://api.elsevier.com/content/abstract/scopus_id/84872793609"}, {"@_fa": "true", "@rel": "scopus", "@href": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84872793609&origin=inward"}, {"@_fa": "true", "@rel": "scopus-citedby", "@href": "https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84872793609&origin=inward"}], "source-id": "15764", "citedby-count": "5", "prism:volume": "54", "subtype": "ar", "dc:title": "Combined renin angiotensin blockade in childhood steroid-resistant nephrotic syndrome", "openaccess": "0", "prism:issn": "13288067 1442200X", "prism:issueIdentifier": "6", "subtypeDescription": "Article", "prism:publicationName": "Pediatrics International", "prism:pageRange": "793-797", "prism:endingPage": "797", "openaccessFlag": "false", "prism:doi": "10.1111/j.1442-200X.2012.03668.x", "prism:startingPage": "793", "dc:identifier": "SCOPUS_ID:84872793609"}, "idxterms": null, "language": {"@xml:lang": "eng"}, "authkeywords": {"author-keyword": [{"@_fa": "true", "$": "Angiotensin II type I receptor blocker"}, {"@_fa": "true", "$": "Angiotensin-converting enzyme inhibitor"}, {"@_fa": "true", "$": "Steroid-resistant nephrotic syndrome"}]}, "subject-areas": {"subject-area": [{"@_fa": "true", "$": "Pediatrics, Perinatology and Child Health", "@code": "2735", "@abbrev": "MEDI"}]}, "authors": {"author": [{"ce:given-name": "Suroj", "preferred-name": {"ce:given-name": "Suroj", "ce:initials": "S.", "ce:surname": "Supavekin", "ce:indexed-name": "Supavekin S."}, "@seq": "1", "ce:initials": "S.", "@_fa": "true", "affiliation": {"@id": "60011189", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189"}, "ce:surname": "Supavekin", "@auid": "12139961000", "author-url": "https://api.elsevier.com/content/author/author_id/12139961000", "ce:indexed-name": "Supavekin S."}, {"ce:given-name": "Wantanee", "preferred-name": {"ce:given-name": "Wantanee", "ce:initials": "W.", "ce:surname": "Surapaitoolkorn", "ce:indexed-name": "Surapaitoolkorn W."}, "@seq": "2", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "60138776", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60138776"}, "ce:surname": "Surapaitoolkorn", "@auid": "55503262600", "author-url": "https://api.elsevier.com/content/author/author_id/55503262600", "ce:indexed-name": "Surapaitoolkorn W."}, {"ce:given-name": "Worrarut", "preferred-name": {"ce:given-name": "Worrarut", "ce:initials": "W.", "ce:surname": "Tancharoen", "ce:indexed-name": "Tancharoen W."}, "@seq": "3", "ce:initials": "W.", "@_fa": "true", "affiliation": {"@id": "60011189", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189"}, "ce:surname": "Tancharoen", "@auid": "55567896600", "author-url": "https://api.elsevier.com/content/author/author_id/55567896600", "ce:indexed-name": "Tancharoen W."}, {"ce:given-name": "Anirut", "preferred-name": {"ce:given-name": "Anirut", "ce:initials": "A.", "ce:surname": "Pattaragarn", "ce:indexed-name": "Pattaragarn A."}, "@seq": "4", "ce:initials": "A.", "@_fa": "true", "affiliation": {"@id": "60011189", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189"}, "ce:surname": "Pattaragarn", "@auid": "7801330585", "author-url": "https://api.elsevier.com/content/author/author_id/7801330585", "ce:indexed-name": "Pattaragarn A."}, {"ce:given-name": "Achra", "preferred-name": {"ce:given-name": "Achra", "ce:initials": "A.", "ce:surname": "Sumboonnanonda", "ce:indexed-name": "Sumboonnanonda A."}, "@seq": "5", "ce:initials": "A.", "@_fa": "true", "affiliation": {"@id": "60011189", "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011189"}, "ce:surname": "Sumboonnanonda", "@auid": "6701903210", "author-url": "https://api.elsevier.com/content/author/author_id/6701903210", "ce:indexed-name": "Sumboonnanonda A."}]}}}